// App-Quantinova.ai

PB0674 : Annualized Bleed Rates in Severe Hemophilia A After Switch to Emicizumab Based on CHESS II Data, Including an Oversample of Emicizumab Patients

Researchers

Presenter

  • M. Mancuso

Principal Investigators

  • F. Nissen

  • H. Zhang

  • J. OHara

  • K. Moreno

  • T. Burke

Medical Centers

  • IRCCS Humanitas Research Hospital, Milan, Lombardia, Italy

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • HCD Economics, Daresbury, United Kingdom

  • HCD Economics and Faculty of Health and Social Care, University of Chester, Daresbury, England, United Kingdom

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

Locations

  • Italy

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved